Skip to main content
/ IR Insights: Recapping our Fifth Annua...
27 March 2024

IR Insights: Recapping our Fifth Annual Vaccines Day

by Moderna
IR Insights Vax Day

Earlier today, Moderna hosted its fifth annual Vaccines Day, where our leadership shared key updates on the Company’s growing infectious disease portfolio. Members of our executive team sat down to dive into key clinical updates across Moderna’s respiratory, latent and other vaccine portfolios, as well as our financial and commercial vaccine strategy. Watch our latest IR Insights video below to hear more from Stéphane Bancel, CEO, Dr. Stephen Hoge, President, Jamey Mock, CFO and Dr. Jackie Miller, SVP and Head of Development for Infectious Diseases.

Stay tuned for more updates and follow us on LinkedIn and Twitter to learn more about Moderna and how we’re changing the future of medicine.

Forward-Looking Statements

This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the advancement of Moderna's programs under clinical development; the timing for anticipated approvals of vaccine candidates; the efficacy, safety and tolerability of vaccine candidates; the total addressable markets for programs under development; the efficiencies and advantages of Moderna's mRNA platform; future capital allocation and financing efforts; and anticipated spending for R&D in 2024. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.